Access cutting-edge ischemic cardiomyopathy treatment through this clinical trial at a research site in Baltimore. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Baltimore location
Preparing your pre-screening questions…
Access ischemic cardiomyopathy specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related ischemic cardiomyopathy treatment provided free
Check if you qualify for this ischemic cardiomyopathy clinical trial in Baltimore, MD
No-Cost Study Care
Local to Baltimore
Convenient for MD residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
Sudden cardiac death (SCD) poses a significant health care challenge with high annual incidence and low survival rates. Implantable cardioverter defibrillators (ICDs) prevent SCD in patients with poor heart function. However, the critical survival benefit afforded by the devices is accompanied by short and long-term complications and a high economic burden. Moreover, in using current practice guidelines of reduced heart function, specifically left ventricular ejection fraction (LVEF)≤35%, as the main determining factor for patient selection, only a minority of patients actually benefit from ICD therapy (\<25% in 5 years). There is an essential need for more robust diagnostic approaches to SCD risk stratification. This project examines the hypothesis that structural abnormalities of the heart itself, above and beyond global LV dysfunction, are important predictors of SCD risk since they indicate the presence of the abnormal tissue substrate required for the abnormal electrical circuits and heart rhythms that actually lead to SCD. Information about the heart's structure will be obtained from cardiac magnetic resonance imaging and used in combination with a number of other clinical risk factors to see if certain characteristics can better predict patients at risk for SCD.
Sponsor: Johns Hopkins University
Yes, this clinical trial (NCT01076660) has an active research site in Baltimore, MD that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for ischemic cardiomyopathy treatment options in Baltimore, MD, this clinical trial (NCT01076660) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Baltimore research site is actively enrolling participants for this clinical trial. You'll receive care from experienced ischemic cardiomyopathy specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all ischemic cardiomyopathy clinical trials near you to find additional studies recruiting in your area.
See all heart attack clinical trials recruiting in Baltimore — not just this study.
Browse Heart Attack Trials in Baltimore →